{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"33.3"},{"groupId":"OG003","value":"16.7"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"60.0"},{"groupId":"OG007","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"8"},{"groupId":"OG006","value":"5"},{"groupId":"OG007","value":"12"}],"units":"Participants"}],"description":"Dose-Limiting Toxicities (DLTs) were defined as cobimetinib-related adverse events occurring within the first 28 days of each administration of cobimetinib.","groups":[{"description":"Dose-Escalation: Participants received 0.6 milligrams per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.","id":"OG000","title":"Phase I (Tablet) Cobimetinib (0.6 mg/kg)"},{"description":"Dose-Escalation: Participants received 0.8 milligrams per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.","id":"OG001","title":"Phase I (Tablet) Cobimetinib (0.8 mg/kg)"},{"description":"Dose-Escalation: Participants received 1 milligram per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.","id":"OG002","title":"Phase I (Tablet) Cobimetinib (1 mg/kg)"},{"description":"Dose-Escalation: Participants received 0.6 milligrams per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.","id":"OG003","title":"Phase I (Suspension) Cobimetinib (0.6 mg/kg)"},{"description":"Dose-Escalation: Participants received 0.8 milligrams per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.","id":"OG004","title":"Phase I (Suspension) Cobimetinib (0.8 mg/kg)"},{"description":"Dose-Escalation: Participants received 1 milligram per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.","id":"OG005","title":"Phase I (Suspension) Cobimetinib (1 mg/kg)"},{"description":"Dose-Escalation: Participants received 1.33 milligrams per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.","id":"OG006","title":"Phase I (Suspension) Cobimetinib (1.33 mg/kg)"},{"description":"Dose-Expansion: Participants received 1 milligram per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.","id":"OG007","title":"Phase II (Suspension) Cobimetinib (1 mg/kg)"}],"paramType":"NUMBER","populationDescription":"The safety evaluable population was defined as all participants who received at least one dose of study drug.","reportingStatus":"POSTED","timeFrame":"Baseline up until 30 days after the last dose of study drug (up to 5 years, 2 months)","title":"Percentage of Participants With Dose-Limiting Toxicities (DLTs)","type":"PRIMARY","unitOfMeasure":"Percentage of Participants"}